Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
Titel:
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
Auteur:
Landovitz, Raphael J Hanscom, Brett S Clement, Meredith E Tran, Ha V Kallas, Esper G Magnus, Manya Sued, Omar Sanchez, Jorge Scott, Hyman Eron, Joe J del Rio, Carlos Fields, Sheldon D Marzinke, Mark A Eshleman, Susan H Donnell, Deborah Spinelli, Matthew A Kofron, Ryan M Berman, Richard Piwowar-Manning, Estelle M Richardson, Paul A Sullivan, Philip A Lucas, Jonathan P Anderson, Peter L Hendrix, Craig W Adeyeye, Adeola Rooney, James F Rinehart, Alex R Cohen, Myron S McCauley, Marybeth Grinsztejn, Beatriz
Verschenen in:
The Lancet. HIV
Paginering:
Jaargang 10 () nr. 12 pagina's e767-e778
Jaar:
2023
Inhoud:
Uitgever:
Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license